Cixutumumab

Drug Profile

Cixutumumab

Alternative Names: A12; IMC-A12; LY3012217; NSC 742460

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator ImClone Systems
  • Developer ImClone Systems; National Cancer Institute (USA)
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Insulin-like growth factor-I receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Colorectal cancer; Head and neck cancer; Hepatocellular carcinoma; Neuroendocrine tumours; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Prostate cancer; Rhabdomyosarcoma; Sarcoma; Soft tissue sarcoma; Solid tumours; Thymoma

Most Recent Events

  • 01 Jul 2016 ImClone completes its phase II trial for Neuroendocrine tumours in (NCT00781911)
  • 30 Jun 2016 Eli Lilly completes its phase II trial for Non-small cell lung cancer in US, Argentina, Brazil, Canada, EU, Israel and Turkey (NCT01232452)
  • 01 May 2016 National Cancer Institute completes a phase I trial in Hepatocellular carcinoma (Combination therapy, Late stage disease, First-line therapy, Unresectable) in USA (NCT01008566)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top